Search

Your search keyword '"Bogdahn, Ulrich"' showing total 909 results
Start Over Author "Bogdahn, Ulrich"
909 results on '"Bogdahn, Ulrich"'

1. Modeling and Bioinformatics Identify Responders to G-CSF in Patients With Amyotrophic Lateral Sclerosis

Author

Johannesen, Siw, Huie, J Russell, Budeus, Bettina, Peters, Sebastian, Wirth, Anna M, Iberl, Sabine, Kammermaier, Tina, Kobor, Ines, Wirkert, Eva, Küspert, Sabrina, Tahedl, Marlene, Grassinger, Jochen, Pukrop, Tobias, Schneider, Armin, Aigner, Ludwig, Schulte-Mattler, Wilhelm, Schuierer, Gerhard, Koch, Winfried, Bruun, Tim-Henrik, Ferguson, Adam R, and Bogdahn, Ulrich

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Neurosciences, Brain Disorders, ALS, Neurodegenerative, Prevention, Rare Diseases, Stem Cell Research, Biomedical Imaging, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Inflammatory and immune system, amyotrophic lateral sclerosis, granulocyte-colony stimulating factor, filgrastim, biomarker, modeling, principal component analysis, cytokines, stem cell, Clinical Sciences, Psychology, Clinical sciences, Biological psychology
Abstract

Objective: Developing an integrative approach to early treatment response classification using survival modeling and bioinformatics with various biomarkers for early assessment of filgrastim (granulocyte colony stimulating factor) treatment effects in amyotrophic lateral sclerosis (ALS) patients. Filgrastim, a hematopoietic growth factor with excellent safety, routinely applied in oncology and stem cell mobilization, had shown preliminary efficacy in ALS. Methods: We conducted individualized long-term filgrastim treatment in 36 ALS patients. The PRO-ACT database, with outcome data from 23 international clinical ALS trials, served as historical control and mathematical reference for survival modeling. Imaging data as well as cytokine and cellular data from stem cell analysis were processed as biomarkers in a non-linear principal component analysis (NLPCA) to identify individual response. Results: Cox proportional hazard and matched-pair analyses revealed a significant survival benefit for filgrastim-treated patients over PRO-ACT comparators. We generated a model for survival estimation based on patients in the PRO-ACT database and then applied the model to filgrastim-treated patients. Model-identified filgrastim responders displayed less functional decline and impressively longer survival than non-responders. Multimodal biomarkers were then analyzed by PCA in the context of model-defined treatment response, allowing identification of subsequent treatment response as early as within 3 months of therapy. Strong treatment response with a median survival of 3.8 years after start of therapy was associated with younger age, increased hematopoietic stem cell mobilization, less aggressive inflammatory cytokine plasma profiles, and preserved pattern of fractional anisotropy as determined by magnetic resonance diffusion tensor imaging (DTI-MRI). Conclusion: Long-term filgrastim is safe, is well-tolerated, and has significant positive effects on disease progression and survival in a small cohort of ALS patients. Developing and applying a model-based biomarker response classification allows use of multimodal biomarker patterns in full potential. This can identify strong individual treatment responders (here: filgrastim) at a very early stage of therapy and may pave the way to an effective individualized treatment option.

Published
2021

2. Reconditioning the Neurogenic Niche of Adult Non-human Primates by Antisense Oligonucleotide-Mediated Attenuation of TGFβ Signaling

Author

Peters, Sebastian, Kuespert, Sabrina, Wirkert, Eva, Heydn, Rosmarie, Jurek, Benjamin, Johannesen, Siw, Hsam, Ohnmar, Korte, Sven, Ludwig, Florian Timo, Mecklenburg, Lars, Mrowetz, Heike, Altendorfer, Barbara, Poupardin, Rodolphe, Petri, Susanne, Thal, Dietmar R., Hermann, Andreas, Weishaupt, Jochen H., Weis, Joachim, Aksoylu, Inci Sevval, Lewandowski, Sebastian A., Aigner, Ludwig, Bruun, Tim-Henrik, and Bogdahn, Ulrich

Published
2021
Full Text
View/download PDF

5. Thoracic rat spinal cord contusion injury induces remote spinal gliogenesis but not neurogenesis or gliogenesis in the brain.

Author

Franz, Steffen, Ciatipis, Mareva, Pfeifer, Kathrin, Kierdorf, Birthe, Sandner, Beatrice, Bogdahn, Ulrich, Blesch, Armin, Winner, Beate, and Weidner, Norbert

Subjects
Cervical Vertebrae, Thoracic Vertebrae, Brain, Spinal Cord, Neuroglia, Animals, Rats, Inbred F344, Spinal Cord Injuries, Contusions, Motor Activity, Nerve Regeneration, Cell Proliferation, Time Factors, Neurogenesis, Rats, Inbred F344, General Science & Technology
Abstract

After spinal cord injury, transected axons fail to regenerate, yet significant, spontaneous functional improvement can be observed over time. Distinct central nervous system regions retain the capacity to generate new neurons and glia from an endogenous pool of progenitor cells and to compensate neural cell loss following certain lesions. The aim of the present study was to investigate whether endogenous cell replacement (neurogenesis or gliogenesis) in the brain (subventricular zone, SVZ; corpus callosum, CC; hippocampus, HC; and motor cortex, MC) or cervical spinal cord might represent a structural correlate for spontaneous locomotor recovery after a thoracic spinal cord injury. Adult Fischer 344 rats received severe contusion injuries (200 kDyn) of the mid-thoracic spinal cord using an Infinite Horizon Impactor. Uninjured rats served as controls. From 4 to 14 days post-injury, both groups received injections of bromodeoxyuridine (BrdU) to label dividing cells. Over the course of six weeks post-injury, spontaneous recovery of locomotor function occurred. Survival of newly generated cells was unaltered in the SVZ, HC, CC, and the MC. Neurogenesis, as determined by identification and quantification of doublecortin immunoreactive neuroblasts or BrdU/neuronal nuclear antigen double positive newly generated neurons, was not present in non-neurogenic regions (MC, CC, and cervical spinal cord) and unaltered in neurogenic regions (dentate gyrus and SVZ) of the brain. The lack of neuronal replacement in the brain and spinal cord after spinal cord injury precludes any relevance for spontaneous recovery of locomotor function. Gliogenesis was increased in the cervical spinal cord remote from the injury site, however, is unlikely to contribute to functional improvement.

Published
2014

6. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial

Author

Funke, Andreas, Kettemann, Dagmar, Meyer, Robert, Meyer, Thomas, Grehl, Torsten, Gruhn, Kai, Schwenkreis, Peter, Stude, Philipp, Heneka, Michael T, Kurzwelly, Delia, Hermann, Andreas, Storch, Alexander, Richter, Nicole, Frank, Tobias, Göricke, Bettina, Hein, Katharina, Emmer, Alexander, Hanisch, Frank, Hanke, Dagmar, Kraya, Torsten, Posa, Andreas, Romanakova, Martina, Schilling, Susanne, Abdulla, Susanne, Böselt, Sebastian, Janssen, Claas, Lange, Imken, Kobeleva, Xenia, Körner, Sonja, Kollewe, Katja, Osmanovic, Alma, Petri, Susanne, Scharn, Nicole, Rath, Klaus J, Dahms, Christiane, Grosskreutz, Julian, Gunkel, Anne, Heiling, Bianka, Ringer, Thomas, Smesny, Uta, Baumeister, Sarah, Berthele, Achim, Bublitz, Sarah, Winkler, Andrea S, Akova-Öztürk, Esra, Boentert, Matthias, Stubbe-Dräger, Bianca, Rahmann, Alexandra, Young, Charlotte, Young, Peter, Baldaranov, Dobri, Bogdahn, Ulrich, Wollebæk Johannesen, Siw, Khomenko, Andrei, Schulte-Mattler, Wilhelm, Stadler, Christina, Husung, Susanne, Prudlo, Johannes, Tesar, Simone, Dargah-Zaden, Nigar, Last, Christina, Langer, Eva, Ludolph, Albert C, Weishaupt, Jochen H, Weiland, Ulrike, Lauenstein, Ann-Sophie, Lensch, Eckard, Mc Farlane, Carolyn, Fischer-Brasse, Heike, Orbán, Klara, Schrank, Bertold, Schürger, Sonja, Klebe, Stephan, Kraft, Peter, Musacchio, Thomas, Seiler, Carola, Zeller, Daniel, Schuster, Joachim, Dorst, Johannes, Dupuis, Luc, Dreyhaupt, Jens, Kassubek, Jan, and Schrank, Berthold

Published
2018
Full Text
View/download PDF

12. SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden

Author

Weyen, Ute, Hermann, Andreas, Regensburger, Martin, Winkler, Jürgen, Linker, Ralf, Winner, Beate, Hagenacker, Tim, Koch, Jan Christoph, Lingor, Paul, Göricke, Bettina, Zierz, Stephan, Jordan, Berit, Baum, Petra, Wolf, Joachim, Winkler, Andrea, Young, Peter, Bogdahn, Ulrich, Prudlo, Johannes, Kassubek, Jan, Yilmaz, Rüstem, Müller, Kathrin, Brenner, David, Volk, Alexander E., Borck, Guntram, Meitinger, Thomas, Strom, Tim M., Danzer, Karin M., Ludolph, Albert C., Andersen, Peter M., and Weishaupt, Jochen H.

Published
2020
Full Text
View/download PDF

13. Data from Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

Author

Lottaz, Claudio, primary, Beier, Dagmar, primary, Meyer, Katharina, primary, Kumar, Praveen, primary, Hermann, Andreas, primary, Schwarz, Johannes, primary, Junker, Markus, primary, Oefner, Peter J., primary, Bogdahn, Ulrich, primary, Wischhusen, Jörg, primary, Spang, Rainer, primary, Storch, Alexander, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 1 from Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma

Author

Beier, Dagmar, primary, Röhrl, Stefanie, primary, Pillai, Deepu R., primary, Schwarz, Stefanie, primary, Kunz-Schughart, Leoni A., primary, Leukel, Petra, primary, Proescholdt, Martin, primary, Brawanski, Alexander, primary, Bogdahn, Ulrich, primary, Trampe-Kieslich, Ariane, primary, Giebel, Bernd, primary, Wischhusen, Jörg, primary, Reifenberger, Guido, primary, Hau, Peter, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

17. Data from Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma

Author

Beier, Dagmar, primary, Röhrl, Stefanie, primary, Pillai, Deepu R., primary, Schwarz, Stefanie, primary, Kunz-Schughart, Leoni A., primary, Leukel, Petra, primary, Proescholdt, Martin, primary, Brawanski, Alexander, primary, Bogdahn, Ulrich, primary, Trampe-Kieslich, Ariane, primary, Giebel, Bernd, primary, Wischhusen, Jörg, primary, Reifenberger, Guido, primary, Hau, Peter, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

Author

Lottaz, Claudio, primary, Beier, Dagmar, primary, Meyer, Katharina, primary, Kumar, Praveen, primary, Hermann, Andreas, primary, Schwarz, Johannes, primary, Junker, Markus, primary, Oefner, Peter J., primary, Bogdahn, Ulrich, primary, Wischhusen, Jörg, primary, Spang, Rainer, primary, Storch, Alexander, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 2 from Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

Author

Lottaz, Claudio, primary, Beier, Dagmar, primary, Meyer, Katharina, primary, Kumar, Praveen, primary, Hermann, Andreas, primary, Schwarz, Johannes, primary, Junker, Markus, primary, Oefner, Peter J., primary, Bogdahn, Ulrich, primary, Wischhusen, Jörg, primary, Spang, Rainer, primary, Storch, Alexander, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma

Author

Beier, Dagmar, primary, Röhrl, Stefanie, primary, Pillai, Deepu R., primary, Schwarz, Stefanie, primary, Kunz-Schughart, Leoni A., primary, Leukel, Petra, primary, Proescholdt, Martin, primary, Brawanski, Alexander, primary, Bogdahn, Ulrich, primary, Trampe-Kieslich, Ariane, primary, Giebel, Bernd, primary, Wischhusen, Jörg, primary, Reifenberger, Guido, primary, Hau, Peter, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 5 from Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

Author

Lottaz, Claudio, primary, Beier, Dagmar, primary, Meyer, Katharina, primary, Kumar, Praveen, primary, Hermann, Andreas, primary, Schwarz, Johannes, primary, Junker, Markus, primary, Oefner, Peter J., primary, Bogdahn, Ulrich, primary, Wischhusen, Jörg, primary, Spang, Rainer, primary, Storch, Alexander, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 1 from Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

Author

Lottaz, Claudio, primary, Beier, Dagmar, primary, Meyer, Katharina, primary, Kumar, Praveen, primary, Hermann, Andreas, primary, Schwarz, Johannes, primary, Junker, Markus, primary, Oefner, Peter J., primary, Bogdahn, Ulrich, primary, Wischhusen, Jörg, primary, Spang, Rainer, primary, Storch, Alexander, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 3 from Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

Author

Lottaz, Claudio, primary, Beier, Dagmar, primary, Meyer, Katharina, primary, Kumar, Praveen, primary, Hermann, Andreas, primary, Schwarz, Johannes, primary, Junker, Markus, primary, Oefner, Peter J., primary, Bogdahn, Ulrich, primary, Wischhusen, Jörg, primary, Spang, Rainer, primary, Storch, Alexander, primary, and Beier, Christoph P., primary

Published
2023
Full Text
View/download PDF

32. Hot-spot KIF5A mutations cause familial ALS

Author

Brenner, David, Yilmaz, Rüstem, Müller, Kathrin, Grehl, Torsten, Petri, Susanne, Meyer, Thomas, Grosskreutz, Julian, Weydt, Patrick, Ruf, Wolfgang, Neuwirth, Christoph, Weber, Markus, Pinto, Susana, Claeys, Kristl G, Schrank, Berthold, Jordan, Berit, Knehr, Antje, Günther, Kornelia, Hübers, Annemarie, Zeller, Daniel, Kubisch, Christian, Jablonka, Sibylle, Sendtner, Michael, Klopstock, Thomas, de Carvalho, Mamede, Sperfeld, Anne, Borck, Guntram, Volk, Alexander E, Dorst, Johannes, Weis, Joachim, Otto, Markus, Schuster, Joachim, Del Tredici, Kelly, Braak, Heiko, Danzer, Karin M, Freischmidt, Axel, Meitinger, Thomas, Strom, Tim M, Ludolph, Albert C, Andersen, Peter M, Weishaupt, Jochen H, Weyen, Ute, Hermann, Andreas, Hagenacker, Tim, Koch, Jan Christoph, Lingor, Paul, Göricke, Bettina, Zierz, Stephan, Baum, Petra, Wolf, Joachim, Winkler, Andrea, Young, Peter, Bogdahn, Ulrich, Prudlo, Johannes, and Kassubek., Jan

Published
2018
Full Text
View/download PDF

33. Direct Potential Modulation of Neurogenic Differentiation Markers by Granulocyte-Colony Stimulating Factor (G-CSF) in the Rodent Brain

Author

Kozole, Judith, Heydn, Rosmarie, Wirkert, Eva, Küspert, Sabrina, Aigner, Ludwig, Bruun, Tim-Henrik, Bogdahn, Ulrich, Peters, Sebastian, and Johannesen, Siw

Subjects
ddc:610, 610 Medizin, Pharmaceutical Science, brain repair, neurodegeneration, neurogenesis, neuronal stem cells, G-CSF, high-dose G-CSF, cellular brain therapy, cerebellum, filgrastim safety
Abstract

The hematopoietic granulocyte-colony stimulating growth factor (G-CSF, filgrastim) is an approved drug in hematology and oncology. Filgrastim’s potential in neurodegenerative disorders is gaining increasingly more attention, as preclinical and early clinical studies suggest it could be a promising treatment option. G-CSF has had a tremendous record as a safe drug for more than three decades; however, its effects upon the central nervous system (CNS) are still not fully understood. In contrast to conceptual long-term clinical application with lower dosing, our present pilot study intends to give a first insight into the molecular effects of a single subcutaneous (s.c.) high-dose G-CSF application upon different regions of the rodent brain. We analyzed mRNA—and in some instances—protein data of neurogenic and non-neurogenic differentiation markers in different regions of rat brains five days after G-CSF (1.3 mg/kg) or physiological saline. We found a continuous downregulation of several markers in most brain regions. Remarkably, cerebellum and hypothalamus showed an upregulation of different markers. In conclusion, our study reveals minor suppressive or stimulatory effects of a single exceptional high G-CSF dose upon neurogenic and non-neurogenic differentiation markers in relevant brain regions, excluding unregulated responses or unexpected patterns of marker expression.

Published
2022

37. Safety of Pregnancy After Cerebral Venous Thrombosis: Results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis)-2 PREGNANCY Study

Author

Aguiar de Sousa, Diana, Canhão, Patrícia, Crassard, Isabelle, Coutinho, Jonathan, Arauz, Antonio, Conforto, Adriana, Béjot, Yannick, Giroud, Maurice, Ferro, José M., Pinho e Melo, Teresa, Pereira, Liliana, Costa, Elisa, Rodrigues, Miguel, Viana Baptista, Miguel, Carvalho, Marta, Lopes, Gabriela, Correia, Manuel, Pinto, Ana Amélia, Coelho, Paulo, Cunha, Luís, Veiga, Andreia, Silva, Mário, Manuela Costa, Maria, Nzwalo, Hipólito, Ferreira, Fátima, Zuurbier, Yvonne, Dequatre-Ponchelle, Nelly, Leys, Didier, Bejot, Yannick, Ruiz-Sandoval, José Luis, Hacke, Werner, Poli, Sven, Gumbinger, Christoph, Nolte, Christian H., Bogdahn, Ulrich, Schlachetzki, Felix, Gerriets, Tibo, Stolz, Erwin, Bastos, Vanessa, Gagliardi, Rubens, Diez-Tejedor, Exuperio, Fuentes, Blanca, Casado-Naranjo, Ignacio, Martinelli, Ida, Scoditti, Umberto, de Veber, Gabrielle, and Lanthier, Sylvain

Published
2017
Full Text
View/download PDF

40. Targeting TGF-ß in the Central Nervous System: Assessment of Cynomolgus Monkey—Toxicity and Pharmacokinetics for an LNA-Antisense Oligonucleotide

Author

Peters, Sebastian Thomas, Wirkert, Eva, Kuespert, Sabrina, Heydn, Rosmarie, Korte, Sven, Mecklenburg, Lars, Aigner, Ludwig, Johannesen, Siw, Bruun, Tim-Henrik, and Bogdahn, Ulrich

Subjects
Fluid Flow and Transfer Processes, Technology, ddc:610, QH301-705.5, Physics, QC1-999, Process Chemistry and Technology, antisense oligonucleotide therapy, neurodegeneration, General Engineering, 610 Medizin, Engineering (General). Civil engineering (General), Computer Science Applications, Chemistry, LNA, TGFß-signaling, ALS, General Materials Science, TA1-2040, Biology (General), QD1-999, Instrumentation
Abstract

Increasingly antisense oligonucleotides (ASOs) are developed for potential treatment of CNS disorders, and due to the inability to cross the blood brain barrier, they require direct administration into the cerebrospinal fluid (CSF). In this regard, intrathecal (i.th.) administration in cynomolgus monkeys (Macaca fascicularis) is a well-established approach for preclinical safety studies. Here, we present an innovative preclinical approach that is intended to support rapid entry into clinical development with ASOs targeting the CNS. The preclinical approach comprises one non-GLP study in 26 non-human primates, followed by a pivotal GLP repeated dose toxicity study in the same species. No pivotal rodent studies were conducted, and regulatory guidance to initiate this study was met by in vitro work. The non-GLP study consists of three separate phases: Phase A determines toxicity after i.th. administrations with five escalating dose levels in a single male and female animal, respectively. Dosing is conducted on days 1, 8, 15, 22, and 29 and the experiment is terminated 36 days after start of the study. The second phase (Phase B) investigates pharmacokinetics over a 2- or 4-week period at two dose levels following single administrations in eight (8) animals (4 females, 4 males). Finally, a third phase (Phase C) investigates toxicity and pharmacokinetics after repeated (9×) dosing over a 13-week period at two dose levels in sixteen (8 females, 8 males) animals. In each phase, clinical observations and physical/neurological parameters are investigated directly pre-dose, 4 h and 24 h post-dose, respectively. In all phases, CSF and blood samples are taken pre-dose and after each dosing, for determination of test article concentration, biomarkers of tolerability and biomarkers of pharmacology. In all phases, tissue samples from the liver, kidney, spinal cord, and brain are collected for determination of NVP-13 tissue concentrations. The above concept has successfully supported first-in-human clinical trials. The entire non-GLP program is completed within less than six months and requires fewer animals in comparison to the conduct of three independent studies.

Published
2022
Full Text
View/download PDF

41. Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders

Author

Peters, Sebastian Thomas, Wirkert, Eva, Kuespert, Sabrina, Heydn, Rosmarie, Johannesen, Siw Wollebæk, Friedrich, Anita, Mailänder, Susanne, Korte, Sven, Mecklenburg, Lars, Aigner, Ludwig, Bruun, Tim-Henrik, and Bogdahn, Ulrich

Subjects
ddc:610, amyotrophic lateral sclerosis, neurodegeneration, antisense oligonucleotide therapy, 610 Medizin, Pharmaceutical Science, GLP-ToxStudy, Article, RS1-441, TGFβ-signaling, neurogenesis, LNA, Pharmacy and materia medica
Abstract

The capability of the adult central nervous system to self-repair/regenerate was demonstrated repeatedly throughout the last decades but remains in debate. Reduced neurogenic niche activity paralleled by a profound neuronal loss represents fundamental hallmarks in the disease course of neurodegenerative disorders. We and others have demonstrated the endogenous TGFβ system to represent a potential pathogenic participant in disease progression, of amyotrophic lateral sclerosis (ALS) in particular, by generating and promoting a disequilibrium of neurodegenerative and neuroregenerative processes. The novel human/primate specific LNA Gapmer Antisense Oligonucleotide “NVP-13”, targeting TGFBR2, effectively reduced its expression and lowered TGFβ signal transduction in vitro and in vivo, paralleled by boosting neurogenic niche activity in human neuronal progenitor cells and nonhuman primate central nervous system. Here, we investigated NVP-13 in vivo pharmacology, safety, and tolerability following repeated intrathecal injections in nonhuman primate cynomolgus monkeys for 13 weeks in a GLP-toxicology study approach. NVP-13 was administered intrathecally with 1, 2, or 4 mg NVP-13/animal within 3 months on days 1, 15, 29, 43, 57, 71, and 85 in the initial 13 weeks. We were able to demonstrate an excellent local and systemic tolerability, and no adverse events in physiological, hematological, clinical chemistry, and microscopic findings in female and male Cynomolgus Monkeys. Under the conditions of this study, the no observed adverse effect level (NOAEL) is at least 4 mg/animal NVP-13.

Published
2022
Full Text
View/download PDF

44. Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders

Author

Peters, Sebastian, primary, Wirkert, Eva, additional, Kuespert, Sabrina, additional, Heydn, Rosmarie, additional, Johannesen, Siw, additional, Friedrich, Anita, additional, Mailänder, Susanne, additional, Korte, Sven, additional, Mecklenburg, Lars, additional, Aigner, Ludwig, additional, Bruun, Tim-Henrik, additional, and Bogdahn, Ulrich, additional

Published
2022
Full Text
View/download PDF

45. Chronic Meningitis

Author

Bogdahn, Ulrich, Wildemann, Brigitte, Einhäupl, Karl M., Hacke, Werner, Hacke, Werner, editor, Hanley, Daniel F., editor, Einhäupl, Karl M., editor, Bleck, Thomas P., editor, Diringer, Michael N., editor, and Ropper, Allan H., editor

Published
1994
Full Text
View/download PDF

49. Modeling and bioinformatics identify responders to G-CSF in patients with amyotrophic lateral sclerosis

Author

Johannesen, Siw, primary, Bogdahn, Ulrich, additional, Bruun, Tim-Henrik, additional, Huie, J. Russell, additional, Ferguson, Adam, additional, Budeus, Bettina, additional, Peters, Sebastian, additional, Wirth, Anna M., additional, Iberl, Sabine, additional, Kammermaier, Tina, additional, Kobor, Ines, additional, Wirkert, Eva, additional, Küspert, Sabrina, additional, Tahedl, Marlene, additional, Grassinger, Jochen, additional, Pukrop, Tobias, additional, Armin, Schneider, additional, Aigner, Ludwig, additional, Schulte-Mattler, Wilhelm, additional, Schuierer, Gerhard, additional, and Koch, Winfried, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results